HopeStage
Back to all studies
CompletedNCT03946111

Naltrexone and Bupropion for Binge Eating After Other Treatments

About this title

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Read the official source — NCT03946111
Medication studyAges 18–64United StatesEating disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 64 years.

Listed locations
New HavenSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 7, 2019
Recruitment status
Completed
Enrollment listed in the registry
3
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT03946111
Official title
Show the full official title

Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Did this study involve medication?

Yes. The study involved medication, including Naltrexone and Bupropion.

Who was this study for?

Listed age limits: 18 years to 64 years.

Want to explore more studies?

Explore studies